| Autor: |
Amber N. Edinoff, C. Austin Casey, Marc A. Colon, Alexa R. Zaheri, Courtney M. Gregoire, Margaret M. Bourg, Alan D. Kaye, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye, Sridhar R. Tirumala, Omar Viswanath, Ivan Urits |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Neurology International, Vol 13, Iss 1, Pp 32-45 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2035-8377 |
| DOI: |
10.3390/neurolint13010004 |
| Popis: |
Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States. Medical treatment of mild to moderate migraines include non-prescription non-steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-containing combination analgesics. Additionally, moderate to severe migraines and those that are mild to moderate that have not responded to analgesics can be treated with triptans, which are drugs specific for migraine treatment. Non-pharmacological treatments include cognitive behavioral therapy and relaxation training. Medications for the prevention of migraines have also been developed since they are more affective in offsetting the symptoms. Ubrogepant’s high specificity and selectivity for calcitonin gene-related peptide (CGRP) sets it apart from certain other drugs, which previously limited the treatment of migraines with or without aura due to their decreased selectivity. The most frequently reported side effects are oropharyngeal pain, nasopharyngitis, and headache. Most studies found that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo. Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to hold promise for the acute treatment of migraines with or without aura in adults. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
